Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601887 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Meloxicam Tablets Under Fed Conditions
A NA study of Inflammation, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00601887 is a NA study of Inflammation that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00601887, a NA study of Inflammation, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Conditions Studied
Interventions
- DRUG Meloxicam
Study Locations (1)
Texas
- Novum Pharmaceutical Research Services - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601887
The ClinicalTrials.gov registry entry for NCT00601887 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (83% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Meloxicam is the first listed.
NCT00601887 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00601887 about?
NCT00601887 is a clinical study titled "Bioequivalency Study of Meloxicam Tablets Under Fed Conditions". The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
What is the current status of trial NCT00601887?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2005-03. Estimated completion is 2005-04.
What conditions does trial NCT00601887 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT00601887?
The interventions under investigation include: Meloxicam (DRUG).
Who is sponsoring clinical trial NCT00601887?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00601887 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Evaluating Whether Hyperbaric Oxygen Therapy Can Improve VO₂-Max and Reduce Inflammation Markers in Healthy Adults Ages 30-60.
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.